%0 Journal Article
%T Oral low-dose estradiol plus norethisterone acetate with or without simvastatin in dyslipidemic and symptomatic menopausal women: A randomized clinical trial
%A Marcelo Luis Steiner
%A Luciano Melo Pompei
%A Rodolfo Strufaldi
%A Everaldo Porto Cunha
%A C¨¦sar Eduardo Fernandes
%J Health
%P 110-118
%@ 1949-5005
%D 2013
%I Scientific Research Publishing
%R 10.4236/health.2013.57A4016
%X <p style=\"text-align:justify;\">
	<span style=\"font-size:10pt;font-family:Verdana;\">Context and
Objective: </span><span style=\"font-size:10pt;font-family:Verdana;\">Cardiovascular diseases are the leading causes of death in postmenopausal
women and dyslipidemia has important contributing factor.</span><span style=\"font-size:10.0pt;font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\"> The objective of the study was to evaluate
low-dose estrogen plus progestogen </span><span style=\"font-family:Verdana;\">therapy
(EPT) + simvastatin for vasomotor symp</span><span style=\"font-family:Verdana;\">toms and lipid and lipoprotein
profiles. Design and Setting: Clinical
trial was conducted in a private clinical research center. Methods: Two hundred forty symptommatic
postmenopausal women with dyslipidemia were randomized to one of three
treatment groups: A) 1 mg estradiol/ 0.5 mg norethisterone acetate (E2/NETA) +
20 mg simvastatin; B) E2/NETA + placebo; or C) 20 mg simvastatin + placebo.
Lipid and lipoprotein profiles and menopausal symptoms were evaluated after
16 weeks. Results: </span></span><span style=\"font-size:10pt;font-family:Verdana;\">Total cholesterol, LDL
cholesterol, non-HDL cholesterol decreased (P &lt; 0.05) in all three groups,
Apo-B/Apo-A1 and ApoB (P &lt; 0.01) in groups A and C and TG and ApoA1 only in
group A comparing baseline versus final. Comparing the groups, group B showed
differences in relation to others in total </span><span style=\"font-size:10pt;font-family:Verdana;\">cholesterol, non-HDL cholesterol, LDL cholesterol, Apo B and ApoB/Apoa1
(P &lt; 0.01). Relief of menopausal symptoms was better compared in A and B. </span><span style=\"font-size:10pt;font-family:Verdana;\">Conclusions:</span><span style=\"font-size:10pt;font-family:'} ';\"><span style=\"font-family:Verdana;\"> Thus in postmenopausal women with
dyslipidemia, the association of E2/ NETA low-dose with simvastatin relieved cli</span><span style=\"font-family:Verdana;\">macteric symptoms similar to that observed with </span><span style=\"font-family:Verdana;\">isolated E2/NETA and improved lipid and lipoprotein profile similar to the
isolated use of simvas</span><span style=\"font-family:Verdana;\">tatin. The use of
E2/NETA alone decreased meno</span><span style=\"font-family:Verdana;\">pausal symptoms, but did not improve
dyslipidemia.</span></span> 
</p>
%K Dyslipidemia
%K Hormone Replacement Therapy
%K Lipoproteins
%K Simvastatin
%K Cardiovascular Diseases
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=34886